BidaskClub upgraded shares of Agenus (NASDAQ:AGEN) from a sell rating to a hold rating in a research report sent to investors on Tuesday, BidAskClub reports.

NASDAQ:AGEN remained flat at $$3.07 during trading hours on Tuesday. 48,660 shares of the company were exchanged, compared to its average volume of 744,833. The company has a market capitalization of $424.29 million, a price-to-earnings ratio of -2.13 and a beta of 1.84. The firm’s 50-day moving average price is $2.70 and its 200-day moving average price is $2.77. Agenus has a one year low of $1.54 and a one year high of $3.88.

Agenus (NASDAQ:AGEN) last issued its earnings results on Thursday, August 8th. The biotechnology company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.05). The company had revenue of $15.72 million for the quarter, compared to the consensus estimate of $5.37 million. Sell-side analysts expect that Agenus will post -1.04 earnings per share for the current fiscal year.

A number of large investors have recently modified their holdings of AGEN. Bank of America Corp DE increased its holdings in shares of Agenus by 111.8% during the 4th quarter. Bank of America Corp DE now owns 150,367 shares of the biotechnology company’s stock valued at $358,000 after purchasing an additional 79,364 shares in the last quarter. BNP Paribas Arbitrage SA raised its holdings in shares of Agenus by 80,579.2% during the 1st quarter. BNP Paribas Arbitrage SA now owns 19,363 shares of the biotechnology company’s stock worth $58,000 after acquiring an additional 19,339 shares during the period. Rhumbline Advisers raised its holdings in shares of Agenus by 5.4% during the 1st quarter. Rhumbline Advisers now owns 118,079 shares of the biotechnology company’s stock worth $351,000 after acquiring an additional 6,064 shares during the period. Shell Asset Management Co. purchased a new position in shares of Agenus during the 1st quarter worth $197,000. Finally, Strs Ohio purchased a new position in shares of Agenus during the 2nd quarter worth $595,000. Institutional investors own 35.96% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.

Featured Article: How to track put option volume

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.